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Abstract
Background: In 2006, the Senegalese National Malaria Control Programme (NMCP) has recommended artemisinin-
based combination therapy (ACT) as the first-line treatment for uncomplicated malaria and, in 2007, mandated testing 
for all suspected cases of malaria with a Plasmodium falciparum HRP-2-based rapid diagnostic test for malaria 
(RDT(Paracheck®). Given the higher cost of ACT compared to earlier anti-malarials, the objectives of the present study 
were i) to study the accuracy of Paracheck® compared to the thick blood smear (TBS) in two areas with different levels 
of malaria endemicity and ii) analyse the cost-effectiveness of the strategy of the parasitological confirmation of 
clinically suspected malaria cases management recommended by the NMCP.
Methods: A cross-sectional study was undertaken in the villages of Dielmo and Ndiop (Senegal) nested in a cohort 
study of about 800 inhabitants. For all the individuals consulting between October 2008 and January 2009 with a 
clinical diagnosis of malaria, a questionnaire was filled and finger-prick blood samples were taken both for microscopic 
examination and RDT. The estimated costs and cost-effectiveness analysis were made considering five scenarios, the 
recommendations of the NMCP being the reference scenario. In addition, a sensitivity analysis was performed 
assuming that all the RDT-positive patients and 50% of RDT-negative patients were treated with ACT.
Results: A total of 189 consultations for clinically suspected malaria occurred during the study period. The sensitivity, 
specificity, positive and negative predictive values were respectively 100%, 98.3%, 80.0% and 100%. The estimated cost 
of the reference scenario was close to 700€ per 1000 episodes of illness, approximately twice as expensive as most of 
the other scenarios. Nevertheless, it appeared to us cost-effective while ensuring the diagnosis and the treatment of 
100% of malaria attacks and an adequate management of 98.4% of episodes of illness. The present study also 
demonstrated that full compliance of health care providers with RDT results was required in order to avoid severe 
incremental costs.
Conclusions: A rational use of ACT requires laboratory testing of all patients presenting with presumed malaria. Use of 
RDTs inevitably has incremental costs, but the strategy associating RDT use for all clinically suspected malaria and 
prescribing ACT only to patients tested positive is cost-effective in areas where microscopy is unavailable.
Background
Malaria is a major cause of morbidity and mortality and
the large, round numbers that delineate its burden have
now become familiar. In 2006, WHO estimated that 3.3
billion persons were at risk of malaria infection of whom
1.2 billion were at high risk, mostly in Africa (49%). Of
the estimated one million annual deaths due to malaria,
approximately 91% of them were thought to occur in
Africa and 85% in children under five years of age [1]. In
Senegal, in 2006, malaria was the first cause of morbidity
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and mortality and was estimated to be responsible for
approximately 35% of the consultations in health care
facilities and 8,000 annual deaths (total estimated popula-
tion 12 million inhabitants). However, in many endemic
countries patients are only clinically diagnosed and a
small proportion of malaria cases are tested, owing to a
lack of diagnostic capabilities. Therefore, there is consid-
erable uncertainty surrounding the estimates of the num-
ber of cases and deaths, mainly in the African region, and
any attempt to establish the number of malaria cases
globally is subject to argument [2]. At the clinic level,
treatments are often given presumptively to patients pre-
senting with fever or other symptoms compatible with
malaria. The emergence and spread of resistance to chlo-
roquine and other anti-malarial drugs have had a dra-
matic impact on the evolution of malaria mortality [3],
especially in Africa [4] and have prompted to change to
more expensive therapeutic combinations. In 2006, the
Senegalese National Malaria Control Programme
(NMCP) has recommended the use of artemisinin-based
combination therapy (ACT) as the first-line treatment for
uncomplicated malaria. These combinations are highly
effective but overall much more expensive than previous
regimens [5]. In this context of increasing direct costs,
rational therapeutic approach against malaria has
become essential and there is a need to limit anti-malarial
treatment to laboratory-confirmed malaria only.
Therefore, as recommended by the World Health Orga-
nization (WHO), rapid diagnostic tests for malaria (RDT)
offer this opportunity. They have the advantage of being
simple to perform, easy to interpret, requiring minimal
infrastructure and thus are particularly indicated where
microscopy, still considered as the gold standard, is not
available. In order to overcome the problems of availabil-
ity of diagnostics the NMCP started in 2007 to provide
h e a l t h  c a r e  f a c i l i t i e s  w i t h  a  r a p i d  d i a g n o s t i c  t e s t  f o r
malaria (RDT). Different types of RDTs based on immu-
nochromatographic antigen capture are marketed.
According to WHO, they must be capable of reliably
detecting 100 parasites/μl (0.002% parasitaemia) from all
Plasmodium spp. with a sensitivity of 100% and of giving
rapid results (15 to 20 minutes) [6]. The most commonly
used RDT target is a glycoprotein called HRP-2 (Histi-
dine Rich Protein 2), an antigen specific for Plasmodium
falciparum  secreted from erythrocytes infected with
rings, trophozoites, schizonts and immature gameto-
cytes. HRP-2-based tests have been shown accurate in
detecting  P. falciparum infections [7]. However, their
specificity is a cause for concern, particularly in areas of
intense malaria transmission due to persistence of HRP2
antigens from previous infections [8,9]. Plasmodium lac-
tate dehydrogenase (pLDH) is the other major targeted
a n t i g e n .  T h is  e n zym e  i s  e x p r es s ed  a t  h i g h  l ev e l s  i n  a l l
blood-stages of the parasite, and all four human malarial
parasites produce a unique pLDH activity. In addition,
pLDH antibodies can also be used to detect Plasmodium
knowlesi  [10], a monkey malaria parasite capable of
infecting humans. The level of pLDH in the blood is
directly linked to the level of parasitaemia. Furthermore,
LDH do not persist in blood after clearance of parasitae-
mia and may be a good marker for both initial diagnosis
of  Plasmodium  infections and while following anti-
malarial efficacy [11]. Lastly, some RDTs detect the fruc-
tose-1,6-diphosphate aldolase, an enzyme of the Plasmo-
dium  glycolytic pathway [12]. Monoclonal antibodies
produced against Plasmodium aldolase are pan-specific
and have been used in combination with HRP-2, making
tests capable of distinguishing an infection with P. falci-
parum from that due to non- P. falciparum.
An earlier study in Senegal showed that HRP-2-based
tests may be especially useful in areas where P falciparum
is predominant and where skilled microscopy is not read-
ily available [13]. In 2007, with help from the Global
Fund, the NMCP implemented a new diagnostic and
treatment guidelines based on the testing of all suspect
cases, with Paracheck® (Orchid Biomedical Systems, Goa,
India), an HRP-2-based test with the objective to achieve
the revised targets set by African Heads of State in Abuja
in 2000, of 80% population coverage by 2010 [14]. The
main objectives of requiring parasitological confirmation
of suspected cases are to avoid costs of treatment of non-
malarial fevers by ACT, to better understand the rates of
disease and death due to malaria in Senegal, to reduce
unnecessary exposure to potential adverse effects of ACT
and to prevent the spread of parasite resistance to these
drugs, already described in Southeast Asia [15-17]. Since
this introduction the country has experienced a dramatic
decrease in malaria-associated morbidity and mortality
(proportional morbidity from 33.6% to 5.6% and propor-
tional mortality from 18.2% to 7.1% between 2006 and
2008 (NMCP, unpublished data), with some of the
decrease likely due to vector control measures put into
place.
The objectives of this study were to evaluate, under
field conditions, the accuracy of Paracheck® compared to
TBS in two areas with different levels of malaria endemic-
ity and to conduct a cost-effectiveness analysis of the
diagnostic and treatment strategy recommended by the
Senegalese NMCP, taking into account the public health
impact of the introduction of ACT and RDTs.
Methods
Study site and population
The study was undertaken in the villages of Dielmo and
Ndiop, located in a sahelo-soudanian region of Senegal
approximately 280 km south-east of Dakar, and 10 km
north of the Gambian border (Figure 1). The Dielmo-
Ndiop project, initiated in 1990 Dielmo and 1993 inLy et al. Malaria Journal 2010, 9:153
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Ndiop respectively is a longitudinal study of host-parasite
relationships and the mechanisms of protective immunity
against malaria. The ongoing longitudinal epidemiologi-
cal and entomologic follow-up at this study site has been
described in detail elsewhere [18]. In April 2008, the pop-
ulation of Dielmo was 460, of whom 424 (92.2%) were
enrolled in the longitudinal follow-up. In this village,
malaria is highly endemic, with intense perennial trans-
mission and an entomologic inoculation rate (EIR) vary-
ing around 200 infected bites/person/year [19]. This high
level of transmission is the result of the permanent pres-
ence of a small river next to the village whose banks host
anopheline larval development sites year round. The vil-
lage of Ndiop, only 5 km far from Dielmo, has 410 inhab-
itants of whom 374 (91%) were enrolled in the study. In
this village, malaria transmission is mesoendemic, with
around 30 infected bites/person/year, and highly sea-
sonal, occurring during the rainy season, from July to
October [20]. For years, the annual number of laboratory
confirmed malaria cases from these two villages has var-
ied from 500 to 700.
The longitudinal follow-up consists of a daily visit to
actively search for suspect cases, the presence of a field
research dispensary, a laboratory, and permanent health
staff in each village. Each suspect case is confirmed using
TBS and, if confirmed, treated with ACT and followed
systematically with TBS at day 4 and 7.
Study design
A cross-sectional study was undertaken at the end of the
rainy season, when a peak of malaria incidence is usually
observed. Included in the study were all individuals from
the Dielmo-Ndiop longitudinal follow-up, consulting at
one of the two field research dispensaries during the
study time period, consenting to participate in this spe-
cific study on RDTs (parent or legal guardian for the chil-
dren), and presenting with a clinically-suspected malaria
(fever or suspicion of fever, cephalgia, diarrhoea or vom-
iting) requiring a TBS. Excluded were individuals pre-
senting with severe malaria or any other severe illness
and those declining to give consent for this study.
Data collection and statistical analysis
For all individuals consulting at the dispensary with a
clinical diagnosis of malaria, finger-prick blood samples
were taken both for microscopic examination, in accor-
dance with the cohort protocol. For each patient
included, a RDT was done and a standardized question-
naire was filled by the health personnel. All RDTs were
carried out and interpreted before reading the blood
smear, following manufacturers' instructions, by techni-
cians present in each village. A second control reading of
the slides was done by an experienced microscopist from
the Institut de Recherche pour le Développement (IRD)
in Dakar who was masked to the RTD and field slide
results. All TBS readings followed a standard protocol,
[21] with a total of 200 microscopic oil-immersion fields
examined (approximately 0.5 μL of blood); which is more
than it is often the case in comparative studies, and the
parasite density estimated from the ratio of the total
number of trophozoites in the 200 fields to the average
number of leucocytes per microscopic field. Gametocytes
were recorded separately and not included in the asexual
parasite count.
The term "episode of illness" refers to any clinically-sus-
pected cases of malaria according to the health worker's
perception while "malaria" refers only to episodes of ill-
ness confirmed by positive control readings of the blood
smears. The sensitivity, specificity, positive and negative
predictive values of RDTs were calculated using the TBS
as the reference test, as recommended by WHO [22].
Confidence intervals of the accuracy indicators were cal-
culated using the exact method. Costing assessment was
undertaken from the NMCP perspective by considering
the non-subsidized costs of RTDs and anti-malarials for
outpatients in public health facilities. The age distribu-
tion of case was taken into account given the treatment
dosage varying according to age groups. Costs were cal-
culated using only direct costs related to the use of RDTs
and ACT. Neither indirect costs (loss of productivity,
infrastructures, other treatments ...) nor those common
to the studied strategies were assessed.
One objective of using RDTs is to limit as much as pos-
sible the prescription of ACT to people who actually have
P. falciparum parasitaemia. For this reason, the primary
measure of effectiveness was the proportion of patients
that would have been correctly managed (proportion of
malaria attacks treated with ACT + proportion of non-
malaria illness with no anti-malarial treatment), the refer-
ence being the result of the blood smear. The secondary
measure of effectiveness was the proportion of all malaria
attacks that would have been treated with ACT. Full com-
Figure 1 Senegal map showing the geographical localization of 
Dielmo and Ndiop villages (Sources Wikitravel.org and Google 
earth).Ly et al. Malaria Journal 2010, 9:153
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pliance of health care providers with tests results was
assumed, what is consistent with some published studies
[23-26].
Five scenarios were considered:
1. Presumptive treatment of all the febrile episodes
of illness (body temperature ≥ 38°C): scenario fre-
quently found in the literature and which supposes
that all febrile episodes of illness are treated with
ACT [27,28].
2. Presumptive treatment of some episodes of ill-
ness according to the healthcare provider's feeling:
here, was taken into account the attitude that the
healthcare provider would have adopted in the
absence of any malaria diagnostic tool. It is a more
pragmatic approach, nearer to the field reality than
the first scenario. It is also the attitude which was pre-
vailing before the RDTs were deployed in Senegal.
3. Treatment of all episodes of illness RDT posi-
tive: it corresponds to the current recommendations
of the Senegalese NMCP, i.e. performing a RDT in
clinically suspected malaria case and prescribing
ACT if tested positive. This was the scenario of refer-
ence.
4. Treatment of febrile episodes of illness with pos-
itive RDT: in this scenario, a RDT is performed in
case of body temperature > 38°C only and ACT pre-
scribed in the event of positive RDT. This scenario,
which can constitute an alternative to the current rec-
ommendations of the NMCP, is also found in the lit-
erature [27,29].
5. Treatment of all children under six and treat-
ment of all episodes of illness RDT positive for
patients over six: a scenario recommended by the
WHO 2006 treatment guidelines.
However, other studies have demonstrated that at least
50% of malaria-negative patients are treated with anti-
malarial drugs [30,31]. For this reason, costs of scenarios
3 to 5 were also estimated using a more realistic figure for
adherence to TDR result, assuming that 50% of malaria-
negative patients were treated with anti-malarials (sensi-
tivity analysis).
Epi-info Version 3.5.1 (CDC, Atlanta, GA, USA) was
used for data entry and Stata Version 10 (StataCorp, Col-
l e g e  S t a t i o n ,  T e x a s ,  U S A )  f o r  s t a t i s t i c a l  a n a l y s i s .  C o s t -
effectiveness analysis results were displayed using the
diagram proposed by Drummond [32].
Ethical approval
The Dielmo-Ndiop program, which was used as support
for this work was approved by the Ministry of Health and
the Prevention's National Ethics Committee in 2006
(Comité National d'Ethique pour la Recherche en Santé).
A separate approval was also obtained from this commit-
tee for the present study. Written informed consents were
obtained from all the participants in the study (or guard-
ians of children under 15 years of age).
Results
Descriptive analysis
A total of 189 consultations for clinically suspected
malaria were recorded between October 2008 and Janu-
ary 2009, 122 in Dielmo and 67 in Ndiop. The proportion
of females was statistically higher than males (59.8%, P <
0.01). The median age of the sample was 5.7 years (Q1-
Q3 interval: 1.2 - 18.2 years). The distribution by age
group was 51.8% under six years, 16.4% from six to 13
years and 31.8% older than 13 years. Age groups were the
same as those used for estimating treatment doses. The
distribution of the sample population by sex and age was
not statistically different between the two villages.
Clinical symptomatology
The most frequent symptom was a history of fever or a
feeling that the body is hot (152 cases - 80.4%). A body
temperature > 38°C was recorded in 94 cases (49.7%) at
the time of the consultation. Headache and weakness
were notified in 57.7% and 49.0% of cases, respectively.
Presumptive anti-malarial treatment
In half the cases (95/189) the health care provider stated
that he would have given ACT on the basis of the clinical
picture and in the absence of means of definitive diagno-
sis of malaria (blood smear or RDT). In the univariate
analysis, body temperature > 38°C, diarrhoea, anorexia
and an age < 6 years were associated with a presumptive
treatment by ACT. The proportion of episodes of illness,
which would have benefited from ACT decreased statisti-
cally with increased age (Chi² for linear trend: P < 0.001).
Parasitological diagnosis of malaria
A total of 189 TBS and 189 RDT were performed at the
initial consultation. Twelve (6.4%) malaria attacks were
confirmed by positive blood smears (8/122 in Dielmo and
4/67 in Ndiop). No discrepancy (positive or negative) was
found in the parasite density between the first reading at
the time of the initial consultation and the control read-
ing. Rapid testing was positive for 15 cases. False positive
RDT results were found in three boys of six months, five
years and 11 years of age living in Dielmo, the village with
higher malaria endemicity. The five year-old had been
treated for slide-positive malaria 14 days prior to inclu-
sion in the study and the 11 year-old showed the presence
of P. falciparum gametocytes on the TBS. The six-month
old child had no clear explanation for the positive RDT
results.
Clinical symptomatology of confirmed cases
A body temperature > 38°C was recorded at the time of
the initial consultation for six (50%) of the 12 cases ofLy et al. Malaria Journal 2010, 9:153
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slide-positive malaria (range 38.2 - 39.8°C). In three (25%)
cases of slide-positive malaria, no fever or history of fever
was recorded. In these three cases, the main symptom
was intense cephalgia. Cases from the two villages were
not significantly different by gender, age, temperature, or
parasite density.
Accuracy of Paracheck® compared to expert microscopy
As the test characteristics for RDTs done in Dielmo and
Ndiop were not significantly different, the data from the
two villages were pooled. Table 1 shows the results of the
test characteristics of Parachek®, in comparison with TBS
readings, by village and for the whole sample. Follow-up
RDT and TBS were performed at D4 and D7 for 10 of the
12 confirmed malaria cases. Of these 10, while the follow-
up TBS readings from D4 were all negative, six (60%) had
a persistent HRP-2 antigenaemia at D4 and four (40%) at
D7. Five (83%) of the six positive RDT at D4 and all four
positive RDT at D7 were from Dielmo.
Cost-effectiveness analysis
Costs
The non-subsidized cost of a treatment course with arte-
sunate-amodiaquine varies according to age: 0.47€ for
children from 1 to 6 years, 0.87€ for children from seven
to 13 years and 1.73€ for both children of more than 13
years and adults. Paracheck® tests cost 0.61€ each. Table 2
gives the estimated costs for 1,000 cases managed accord-
ing to each scenario, assuming that the age distribution is
the same as that observed in the study sample. Except for
scenario 5, the estimated cost of the reference scenario
was close to 700€ per 1,000 episodes of illness, roughly
double the three other scenarios, where the estimated
cost was around 350 € per 1,000 episodes of illness. The
approximate increase in costs for the reference scenario
ranged between 330 and 350€ per 1,000 episodes of ill-
ness.
Effectiveness
Scenarios 1 and 2, i.e. those based on the presumptive
treatment of suspected malaria, would have resulted in
the correct management of only half of the episodes of ill-
ness while scenarios 3 and 4, based on the use of the RDT,
would have resulted in correct management of nearly all
of the episodes (98.4% and 95.8%, respectively). The
effectiveness of scenario 5 was estimated between these
two values (58.2%). However, considering the secondary
measure of effectiveness, scenario 4 would have resulted
in ACT treatment for only half of the malaria attacks.
Table 3 shows the proportion of episodes of illness with
adequate management for each scenario.
Cost-effectiveness analysis
Figure 2 shows the cost-effectiveness analysis for the pri-
mary measure of effectiveness (proportion of episodes of
illness correctly managed). All four scenarios lie in the
left lower quadrant of the graph (less expensive but also
less effective than the reference). Compared to the refer-
ence scenario, the others were neither dominant (less
costly and more effective) nor dominated (more costly
and less effective). Based on the primary measure of
effectiveness, scenario 4 seemed to be a reasonable alter-
native, as it was half as expensive and equally effective as
the reference scenario. However, considering the second-
ary measure of effectiveness, the proportion of malaria
attacks that would have benefited from an anti-malarial
treatment (Figure 3), scenario 4 would adequately man-
age only half the malaria attacks and thus would be no
more effective than the presumptive treatment strategies.
Still considering this secondary measure of effectiveness,
scenario 5 appeared to be less costly while as effective as
the reference scenario.
Sensitivity analysis
Costs of scenarios 3 to 5 were estimated assuming that all
the RDT-positive patients and 50% of RDT-negative
patients were treated with ACT. Costs of each scenario
were estimated to be around 1.5 fold higher than when
assuming full compliance to the test results (Table 4).
Under this assumption, the proportions of episodes of ill-
ness correctly managed were estimated of 52.4% and
54.3% for scenarios 3 and 4, respectively. This proportion
dropped to 29.6% in scenario 5.
Table 1: Accuracy assessment of Paracheck®, by village and for the whole sample
RDT characteristic Village Total sample (N = 189)
Dielmo (n = 122) Ndiop (n = 67) (%) 95%CI*
Sensitivity 100 100 100 [73.5 - 100]
Specificity 97.4 100 98.3 [95.1 - 99.6]
Positive Predictive Value 72.7 100 80.0 [51.9 - 95.7]
Negative Predictive Value 100 100 100 [97.9 - 100]
* 95%CI : 95% Confidence Interval (exact method)Ly et al. Malaria Journal 2010, 9:153
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Table 2: Costs comparison (in Euros) between the four scenarios, estimated on the 189 episodes of illness (October 2008 
and January 2009).
Age distribution (n) Cost of RDT & ACT Total cost (study sample) Cost per 1000 EI* cost difference with 
scenario3 (per 1000 EI) & 
95%CI
Scenario 1: Presumptive treatment of all the febrile EI*
(number of RDT = 0, number of ACT course = 94)
RDT cost 0
ACT cost 66,68 66,68 352,8 - 336,3 [-320,0 ; -355,0]
1-6 y 70 32,9
7-13 y 9 7,83
> 13 y 15 25,95
Scenario 2: Presumptive treatment of EI* according to the healthcare provider's feeling
(number of RDT = 0, number of ACT course = = 95)
RDT cost 0
ACT cost 68,35 68,35 361,6 - 327,5[ -311,2 ; -346,2]
1-6 y 68 31,96
7-13 y 12 10,44
> 13 y 15 25,95
Scenario 3: Treatment of all EI* RDT positive
(number of RDT = 189, number of ACT course = 15 [12 ; 19])
RDT cost 115,29 689,10
ACT cost 14,95 130,24 [672,8 ; 707,8] Reference.
1-6 y 6 2,82
7-13 y 4 3,48
> 13 y 5 8,65
Scenario 4: Treatment of febrile EI* RDT positive
(number of RDT = 94, number of ACT course = 8 [6 ;11])
RDT cost 57,95 335,3
ACT cost 5,42 63,37 [328,0 ; -346,0] - 353,8 [-326.8 ; -379,8]
1-6 y 6 2,82
7-13 y > 13 y 1 1 0,87 1,73
Scenario 5: Treatment of all children ≤ 6 and of all episodes of illness RDT positive for patients > 6
(number of RDT = 91, number of ACT course = 107 [105 ; 109])
RDT cost 55.51 601,6
ACT cost 58.19 113.7 [587,8 ; 615.3] -87.5 [-57.5 ; -120.0].
1-6 y 98 46.06
7-13 y 4 3,48
> 13 y 5 8,65
* EI = Episode of illnessLy et al. Malaria Journal 2010, 9:153
http://www.malariajournal.com/content/9/1/153
Page 7 of 11
Discussion
Accuracy of rapid testing
The accuracy of rapid testing was very good compared to
TBS. At D0, sensitivity, specificity, positive and negative
predictive values were of 100%, 98.3%, 80% and 100%,
respectively. These results are consistent with other pub-
lished studies showing that the sensitivity and specificity
of HRP-2-based tests usually are > 90% for P. falciparum
[9,33,34] and that they can be a useful tool in the manage-
ment of patients with suspected malaria, especially where
microscopic diagnosis is not available [35,36]. However,
the results observed can vary according to transmission
intensity [37]. In zones of high transmission, the specific-
ity of these tests can be lower. Studies performed In the
Democratic Republic of Congo in children aged 6-59
m o n t h s  [ 3 8 ]  a n d  i n  a  h ype r e n d e m i c  r e gi o n  o f  U g a n d a
[39] found 52% to72% specificity for the HRP-2 based test
they evaluated. A lower specificity was also found in
Dielmo where all three false positive results were
recorded, though only one child had a history of a prior
malaria episode. The specificity of these tests is usually
higher in low malaria transmission areas like Ndiop, simi-
lar to what was found in an urban area in Tanzania [40].
H o w e v e r ,  i n  l o w  e n d e m i c i t y  a r e a s ,  s o m e  a u t h o r s
described a lower sensitivity, related to a low parasitae-
mia rate [41-43], which was not observed in the study in
Ndiop. The persistence of HRP-2 antigenaemia after
effective treatment is thought to be the most frequent
cause of false positive results for HRP-2-based RDT [44].
In the present study as well, 60% of RDT carried out on
D4 and 40% carried out on D7 were still positive, corre-
sponding to a specificity of the RDT of 40% at D4 and
60% at D7. Other studies showed that 35% to 61% of
patients still had HRP-2 antigenaemia 14 days after treat-
ment [45,46] and that this antigenaemia could persist up
to 35 days after treatment [38,39].
Another cause of false positive results with HRP-2-
based tests found in Dielmo is the presence of early
gametocytes [47,48]. The third case of false positive RDT
results was a six-month old child who had neither recent
history of fever nor any other obvious reason for a posi-
tive result. It is possible that this "false positive" result was
due to a temporary and asymptomatic parasitaemia dur-
ing the weeks preceding the test in a child still protected
by maternal antibodies or to a parasitaemia lower than
the threshold of microscope detection [37,44].
Cost-effectiveness analysis
Through scenario 2, this study took into account the atti-
tude of the healthcare personnel whether or not to pre-
scribe ACT in clinically suspected cases of malaria when
estimating costs. Although studies assume that only
febrile patients are considered to have malaria, in reality
almost 20% of anti-malarials are given to patients who do
not have a history of fever [49]. While this study only took
account of direct costs related to the use of the ACT and
RDT, other studies have taken into account other param-
eters like the costs of microscopy (materials and staff
time), the cost of any second line treatment and antibiot-
ics, or health outcomes in terms of disability-adjusted life
years averted [25,34]. Unlike Zikuzooka's findings [28],
the present study did not show that using RDTs could be
cost-saving and it is likely that the cost of the additional
benefit brought by RDTs may be higher than many coun-
tries can afford without external assistance or lower RDT
prices [24].
This study confirmed the high operational accuracy of
Paracheck® but also shows the increased risk of false-posi-
tive results as transmission increases, probably related to
persistent antigenemia after treatment, that could lead to
misdiagnoses and thus of inappropriate prescriptions of
ACT. However, in Senegal zones of high endemicity
Table 3: Proportion of correctly managed episodes of illness or malaria attacks for the four scenarios considered.
Malaria attack (N = 12) Non-malaria attack (N = 177) Total EI* (N = 189)
Treated with ACT Non-treated with ACT Non-treated with ACT Treated with ACT Episodes of illness with adequate 
management
n (%) n (%) n (%) n (%) n (%) [IC95%]
Scenario 1 6 (50.0) 6 (50.0) 89 (50.3) 88 (49.7) 95 (50.3) [42.9 ;57.6]
Scenario 2 8 (66.7) 4 (33.3) 90 (50.8) 87 (49.2) 98 (51.8) [44.5 ;59.2]
Scenario 3 12 (100) 0 (00.0) 174 (98.3) 3 (1.7) 186 (98.4) [95.4 ;99.6]
Scenario 4 6 (50.0) 6 (50.0) 175 (98.9) 2 (1.1) 181 (95.8) [91.8 ;98.1]
Scenario 5 12 (100) 0 (00,0) 98 (55.4) 79 (44.6) 110 (58.2) [50.8 ;65.3]
* EI = Episode of illnessLy et al. Malaria Journal 2010, 9:153
http://www.malariajournal.com/content/9/1/153
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remain limited and the most representative epidemio-
logic setting is the strictly seasonal transmission of
Ndiop. Under the scenarios based on rapid testing (3 and
4), ACT would have been prescribed in only 1.7% to
11.3% of the non-malaria episodes of illness, while under
the scenarios based on clinical diagnosis (1 and 2) this
proportion would reach nearly 50%, consistent with Lux-
emburger's findings [50]. This analysis also confirms that
RDTs are good tools for malaria diagnosis where micros-
copy is unavailable and for reducing the risk of clinical
failure with presumptive treatment [42]. In addition,
RDT s make it possible to collect more reliable data on
malaria epidemiology and its proportional morbidity and
mortality. Malaria represented only 3.2% of the episodes
of illness and 6.4% of the cases of fever in the present
study. In other studies, this RDT positivity rate ranges
from 6 to 52% of clinically diagnosed malaria cases in
areas of low-moderate transmission [8] and can reach
87% in high-transmission areas [23]. It is, therefore, nec-
essary to encourage and train healthcare personnel to
consider other diseases besides malaria as the cause of
fever.
The cost of the scenario corresponding to the current
recommendations of the NMCP in Senegal was estimated
around 700€ per 1,000 episodes of illness, approximately
twice as expensive as the others scenarios considered,
except for scenario 5. Nevertheless, it still appeared to us
cost-effective as it ensured the correct diagnosis and
treatment of 100% of malaria attacks and an adequate
management of 98.4% of episodes of illness. The other
scenarios, while less costly, were also less effective. Sce-
nario 4 was close to the reference scenario when consid-
ering the primary measure of effectiveness, but it would
have resulted in the correct diagnosis and treatment of
o n l y  5 0 %  o f  m a l a ria  cas es  a n d  t h us  ca n n o t  be  r ec o m -
mended for ethical and public health reasons. Scenario 5
could be a possible alternative to the reference scenario
when the primary measure of effectiveness is considered.
However, the sensitivity analysis of the present study
demonstrated that full compliance of health care provid-
ers with RDT results was required in order to avoid
severe incremental costs.
Studies undertaken in sub-Saharan Africa have shown
that, when ACT is used, confirming cases with RDTs was
cost-effective compared to presumptive treatment when
the parasite prevalence was below 62% and may help to
improve management of non-malaria febrile illness, par-
ticularly bacterial infections [25,51]. However, the speci-
ficity of RDTs and results of cost-effectiveness analyses
should be interpreted considering the level of endemicity,
season, age of patients or presence/absence of fever dur-
ing consultation [8], and whether patients with RDT neg-
ative results are prescribed anti-malarial as has been
frequently shown to be the case [30,31]. Given the greater
burden of malaria in Africa, economic analyses can be
very sensitive to small changes in the cost of treatment or
diagnosis [24]. In the future RDTs should become more
cost-effective as the Senegalese NMCP completes its plan
to replace the current ACT with a better tolerated but
more expensive one and as the risk of malaria is reduced
[28].
Limitations
A limitation of this study was the low malaria incidence
during recruitment. This incidence was the lowest
observed since the Dielmo-Ndiop cohort follow-up was
begun in 1990. Such a drop in incidence, observed follow-
ing the deployment of ACT and vector control measures
in Senegal and described elsewhere [52], would only
improve the cost-effectiveness of RDT use. Another limi-
tation was that only costs of anti-malarial treatment and
Figure 2 Cost-effectiveness analysis comparing four scenarios 
(primary measure of effectiveness: proportion of episodes of ill-
ness with adequate management).
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Figure 3 Cost-effectiveness analysis comparing four scenarios 
(secondary measure of effectiveness: proportion of malaria at-
tacks that would have benefited from ACT).
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diagnostic testing were included and not indirect costs
such as those related to management of patients initially
wrongly diagnosed, productivity losses or treatment costs
of non-malaria cases.
Conclusions
According to the results of the present study, strategies
based on presumptive treatments of clinically suspected
malaria, or febrile illnesses, or on performing RDT in
case of fever only lead to a high level of misdiagnosis.
In settings where microscopy is unavailable, using RDT
can lead to a significant reduction in the overprescription
of anti-malarials [53] Though the use of RDTs has inevi-
table incremental costs, such an investment offers a more
promising strategy to deal with increasing costs of ther-
apy driven by drug resistance [34]. This strategy results in
a rational use of ACT and ensure their sustainability in
limiting improper treatments leading to drug wastage
and resistance [54]. In addition, confirming all cases with
RDTs will provide more reliable data on malaria epidemi-
ology.
The present study confirmed the benefits in promoting
the use of RDTs in remote areas where microscopy is
unavailable. However, it will be necessary to repeat these
studies as malaria epidemiology changes and to test RDTs
targeting both falciparum and non-falciparum parasites.
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